Abstract Library

#3354 Cancer associated fibroblasts induce proliferation and therapeutic resistance in neuroendocrine tumors through STAT3 activation

Introduction: Cancer-associated fibroblasts (CAF) have been identified as relevant contributors to cancer progression and drug resistance in many tumors. Although neuroendocrine tumors (NET) are often associated with a strong stromal reaction, no study has addressed whether CAF are involved in progression and therapeutic resistance in NET.

Conference:

Presenting Author:

Authors: Amin T, Viol F, Fahl M, Eggers C, Awwad F,

Keywords: neuroendocrine tumor, cancer associated fibroblasts, NT-3, cell lines,

#3252 Streptozotocin resistant pancreatic neuroendocrine tumor cell lines as a tool to understand chemotherapy resistance in pNET

Introduction: Streptozotocin based chemotherapy is standard of care in patients with advanced pancreatic neuroendocrine tumors (pNET). Although partial remission can initially be achieved in up to 40% of patients, primary non-responders and development of secondary progression under therapy is a major clinical challenge. So far, the mechanism leading to streptozotocin resistance have not been elucidated.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Schrader J

Authors: Viol F, Amin T, Fahl M, Izbicki J, Schrader J,

Keywords: streptozotocin, pNET, MGMT,

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2270 Development of Pre-Clinical NEN Models – Limitations and Opportunities

Introduction: Pre-clinical research in neuroendocrine neoplasia (NEN) has long been impaired by the paucity of NET and NEC cell lines. Furthermore, established models have not been widely available or displayed unusual features (eg. p53 and ras mutations, high proliferation rate).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Schrader J

Authors: Schrader J, Benten D, Unrau L, Fahl M, Eggers C,

Keywords: cell line,

#2113 How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms

Introduction: Liver specific MR contrast agents in neuroendocrine neoplasms (NEN) have shown its advantages in evaluation of hepatic tumor burden. However, a standard scan protocol is insufficient in extrahepatic and especially pelvic tumor evaluation.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fehrenbach U

Authors: Fehrenbach U, Fahlenkamp U, Prasad V, Pavel M, Geisel D,

Keywords: magnetic resonance, hepatocyte specific, liver specific, gadoxetate, gadoxetic acid, neuroendocrine, staging, shuttle, large bore, whole abdomen, pelvis, extrahepatic evaluation,